Refeyn, a pacesetter in mass photometry know-how, declares the launch of its macro mass photometry platform, KaritroMP. This new benchtop instrument marks an evolutionary step past mass photometry, permitting for the characterization of enormous viral vectors, together with adenovirus vectors (AdVs) and lentivirus vectors (LVVs). Providing quick, easy, and qualitative evaluation, KaritroMP can inform the R&D of gene and cell therapies, and vaccines.
In contrast to classical mass photometry know-how, KaritroMP makes use of mild scattering to measure each the scale and distinction of single particles, permitting for big particles comparable to AdVs and LVVs to be characterised throughout two dimensions. Utilizing these measurements, populations of comparable dimension however with completely different lots might be resolved, enabling the evaluation of the ratio of empty vs full AdV capsids, along with detection of any crude or degraded particles current. This supplies important knowledge on viral vector traits, together with stability, purity, and high quality. Consequently, this strategy can streamline viral vector course of growth and optimization, permitting customers to simply and shortly evaluate completely different manufacturing and purification strategies, and assess batch-to-batch variation.
Key benefits of the KaritroMP are its pace and ease of use. This benchtop instrument takes simply six minutes to research a pattern, and may achieve this autonomously with as much as 13 samples utilizing built-in custom-built software program. The semiautomated workflow requires little pattern, and with fast preparation steps and simple operation, the operational effectivity of analytical processes might be dramatically elevated.
“We’re very excited to announce the launch of the KaritroMP” states Matthias Langhorst, CPO at Refeyn. “With this new know-how, giant viral vectors might be characterised in a brand new method that can be straightforward to make use of and quick. We’re wanting ahead to seeing our prospects understand the advantages of this progressive analytical strategy on the event of their cell and gene therapies and vaccines.”
The launch of this new platform exemplifies Refeyn’s dedication to pushing the boundaries of single particle evaluation with its pioneering mass photometry applied sciences – supporting the biopharmaceutical business and facilitating groundbreaking developments. Enabling quick, easy, and reproducible evaluation of single particles together with viral vectors, Refeyn continues to pave the way in which for environment friendly and high-quality analytical workflows, to assist streamline the method growth of novel therapeutics.